EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Hantaviral therapeutics: life cycle targets and chemotherapeutic interventions

Deren Zehra Kocabiyik, Jansen de Araujo, Edison Luiz Durigon, Carsten Wrenger

Frontiers in Cellular and Infection Microbiology · 2026

DOI: 10.3389/fcimb.2026.1972830 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Deren Zehra Kocabiyik und 3 weiteren Autor:innen. Beteiligte Einrichtung: Unit for Drug Discovery, Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Hauptthemen laut MEDLINE: Antiviral Agents, Orthohantavirus, Hantavirus Infections. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Orthohantaviruses represent a persistent global health threat, being responsible for life-threatening diseases such as Hemorrhagic Fever with Renal Syndrome (HFRS) and Hantavirus Cardiopulmonary Syndrome (HCPS). Despite high case fatality rates and recent outbreaks, there are currently no universally licensed antivirals or vaccines. Clinical management remains heavily reliant on supportive care and repurposed drugs, which often exhibit limited efficacy and dose-limiting toxicities. This review examines rational drug design strategies targeting critical steps in the viral life cycle, specifically Gn/Gc-mediated cellular entry and RNA-dependent RNA polymerase (RdRp)-driven genome replication. We evaluate the current landscape of viral inhibitors, including peptidomimetics, nucleoside analogues, and naturally derived compounds. To accelerate the discovery of novel treatments, we advocate for the integration of modern in silico screening to evaluate extensive chemical and natural product libraries. These broad compound collections offer a structurally diverse and largely untapped reservoir for antiviral development. Ultimately, expanding preclinical testing to include globally neglected variants will be essential to develop broad-spectrum hantaviral therapeutics capable of mitigating future epidemic threats.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsOrthohantavirusHantavirus InfectionsHumansVirus InternalizationVirus ReplicationAnimalsDrug DiscoveryDrug DesignRNA-Dependent RNA Polymerase

Stichwörter der Autor:innen

RNA-dependent RNA polymerase (RdRp) inhibitorsantiviral discoverychemotherapeuticsdrug developmentorthohantavirusphytochemicalsviral entry inhibitorsviral life cycle targets

Substanzen

Antiviral AgentsRNA-Dependent RNA Polymerase

Autor:innen und Institutionen

  • Unit for Drug Discovery, Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
  • Institut Pasteur de São Paulo, São Paulo, Brazil.
  • Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.

Förderung

  • Fundação de Amparo à Pesquisa do Estado de São Paulo

Zitieren

APA

Kocabiyik, D. Z., de Araujo, J., Durigon, E. L., & Wrenger, C. (2026). Hantaviral therapeutics: life cycle targets and chemotherapeutic interventions. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1972830

Vancouver

Kocabiyik DZ, de Araujo J, Durigon EL, Wrenger C. Hantaviral therapeutics: life cycle targets and chemotherapeutic interventions. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.1972830

BibTeX
@article{Kocabiyik2026,
  author = {Kocabiyik, Deren Zehra and de Araujo, Jansen and Durigon, Edison Luiz and Wrenger, Carsten},
  title = {Hantaviral therapeutics: life cycle targets and chemotherapeutic interventions},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  doi = {10.3389/fcimb.2026.1972830}
}
Kostenlos starten →